Actavis and Valeant Announce Actavis as Exclusive Authorized Generic Marketer of Zovirax® Ointment; Co-Promotion Agreements on

Actavis and Valeant Announce Actavis as Exclusive Authorized Generic Marketer 
of Zovirax® Ointment; Co-Promotion Agreements on Zovirax® Cream and 
Cordran® Tape 
PARSIPPANY, N.J. and MONTREAL, April 5, 2013 /CNW/ - Actavis, Inc. (NYSE: 
ACT), and Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) 
today announced that they have entered into an agreement, effective 
immediately, for Actavis to be the exclusive marketer and distributor of an 
authorized generic of Valeant's Zovirax® ointment (acyclovir 5%) product.  
Additionally, Valeant has granted Actavis the exclusive right to co-promote 
Zovirax® cream (acyclovir 5%) to obstetricians and gynecologists in the U.S., 
and Actavis has granted Valeant the exclusive right to co-promote Actavis 
Specialty Brands' Cordran® Tape (flurandrenolide) product in the U.S. 
Zovirax Authorized Generic Agreement Under the terms of the exclusive 
Zovirax® ointment agreement, Valeant will supply Actavis with a generic 
version of Valeant's Zovirax® ointment product and Actavis will market and 
distribute the product in the United States. Actavis will record all of the 
net sales of the generic ointment product and Valeant will receive a share of 
the economics. Other terms of the agreement have not been disclosed. 
Zovirax® Cream and Cordran® Tape Co-Promotion Agreements Under terms of the 
agreement related to the co-promotion of Zovirax® cream, Actavis will utilize 
its existing Specialty Brands sales and marketing structure to promote the 
product and will receive a co-promotion fee from sales generated by 
prescriptions written by its defined targeted physician group.  Under the 
terms of the Cordran® Tape co-promotion agreement, Valeant will utilize its 
existing Dermatology sales and marketing structure to promote the product, and 
will receive a co-promotion fee on sales.  Each party will retain all rights 
in and to its respective products and trademarks including booking of sales. 
Other terms of the agreement have not been disclosed. 
Zovirax® cream 5% is indicated for the treatment of recurrent herpes labialis 
(cold sores) in adults and adolescents (12 years of age and older). Zovirax® 
ointment 5% is indicated in the management of initial genital herpes and in 
limited non-life-threatening mucocutaneous herpes simplex virus infections in 
immunocompromised patients. 
Cordran® Tape, a potent corticosteroid for topical use, is a transparent, 
waterproof medicated tape used to treat the inflammation and itching caused by 
a number of skin conditions such as allergic reactions, eczema and psoriasis. 
About Actavis, Inc. Actavis, Inc. (NYSE: ACT) is a global, integrated 
specialty pharmaceutical company focused on developing, manufacturing and 
distributing generic, brand and biosimilar products.  The Company has global 
and U.S. headquarters in Parsippany, New Jersey, USA, and international 
headquarters in Zug, Switzerland. 
Actavis is the world's third-largest generics prescription drug manufacturer.  
Operating as Actavis Pharma, the Company develops, manufactures and markets 
generic, branded generic, legacy brands and Over-the-Counter (OTC) products in 
more than 60 countries.  The Company is ranked in the top 3 in 12 global 
markets, the top 5 in 16 global markets, and in the top 10 in 33 global 
markets.   Actavis Pharma also develops and out-licenses generic 
pharmaceutical products outside the U.S. through its Medis third-party 
business, the world's largest generic pharmaceutical out-licensing business. 
Medis has more than 300 customers globally, and offers a broad portfolio of 
more than 200 products. 
Actavis Specialty Brands is the Company's global branded specialty 
pharmaceutical business, which develops and markets a portfolio of 
approximately 40 products principally in the United States and Canada that are 
focused in the Urology and Women's Health therapeutic categories.  Actavis 
Specialty Brands is committed to developing and marketing biosimilars products 
in Women's Health, Oncology and other therapeutic categories, and currently 
has a portfolio of 5 biosimilar products in development. 
Actavis Global Operations has more than 30 manufacturing and distribution 
facilities around the world, with a capacity of approximately 44 billion units 
annually.  Actavis Global Operations also includes Anda, Inc., the 
fourth-largest U.S. generic pharmaceutical product distributor in the United 
States. 
For press release and other company information, visit Actavis' Web site at 
http://www.actavis.com. 
About Valeant Pharmaceuticals International, Inc. Valeant Pharmaceuticals 
International, Inc. (NYSE/TSX: VRX) is a multinational specialty 
pharmaceutical company that develops, manufactures and markets a broad range 
of pharmaceutical products primarily in the areas of dermatology, neurology,  
and branded generics. More information about Valeant Pharmaceuticals 
International, Inc. can be found at www.valeant.com. 
Actavis Forward-Looking Statement  Statements contained in this press release 
that refer to non-historical facts are forward-looking statements that reflect 
Actavis' current perspective of existing information as of the date of this 
release. It is important to note that Actavis' goals and expectations are not 
predictions of actual performance. Actual results may differ materially from 
Actavis' current expectations depending upon a number of factors affecting 
Actavis' business. These factors include, among others, the inherent 
uncertainty associated with financial projections; the difficulty of 
predicting the timing or outcome of FDA approvals or actions, if any; the 
impact of competitive products and pricing; the timing and success of product 
launches; difficulties or delays in manufacturing; the availability and 
pricing of third party sourced products and materials; successful compliance 
with FDA and other governmental regulations applicable to Actavis and its 
third party manufacturers' facilities, products and/or businesses; and such 
other risks and uncertainties detailed in Actavis' periodic public filings 
with the Securities and Exchange Commission, including but not limited to 
Actavis' annual report on Form 10-K for the year ended December 31,2012. 
Except as expressly required by law, Actavis disclaims any intent or 
obligation to update these forward-looking statements. 
Valeant Forward-Looking Statement This press release contains forward-looking 
statements regarding, among other things, the future supply, marketing, 
promotion and distribution of products.  Statements including words such as 
"believes," "expects," "anticipates," "intends," "estimates," "plan," "will," 
"may," "intend," "guidance" or similar expressions are forward-looking 
statements.  Because these statements reflect Valeant's current views, 
expectations and beliefs concerning future events, these forward-looking 
statements involve risks and uncertainties. Investors should note that many 
factors could cause actual results to differ materially from those expressed 
in forward-looking statements contained in this press release. These factors 
include, but are not limited to the market acceptance of products and other 
risks and uncertainties, including those detailed from time to time in 
Valeant's periodic reports filed with the Securities and Exchange Commission 
("SEC") and the Canadian Securities Administrators ("CSA"), including current 
reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 
10-K, particularly the discussion under the caption "RISK FACTORS" in 
Valeant's annual report on Form 10-K for the year ended December 31, 2012, 
which have been filed with the SEC and the CSA. The forward-looking statements 
in this press release are qualified by these risk factors. These are factors 
that, individually or in the aggregate, could cause Valeant's actual results 
to differ materially from expected and historical results. Valeant assumes no 
obligation to publicly update any forward-looking statements, whether as a 
result of new information, future developments or otherwise. 
(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO) 
Actavis: Investors: Lisa DeFrancesco  (862) 261-7152 
Media: Charlie Mayr (862) 261-8030  
Valeant: Laurie W. Little (949) 461-6002 
http://www.valeant.com 
http://photos.prnewswire.com/prnh/20101025/LA87217LOGO 
PRN Photo Desk, photodesk@prnewswire.com 
SOURCE: Valeant Pharmaceuticals International, Inc. 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/April2013/05/c2956.html 
CO: Valeant Pharmaceuticals International, Inc.
ST: New Jersey
NI: HEA MTC ORDER  
-0- Apr/05/2013 12:01 GMT